Drug General Information |
Drug ID |
D0Q0PO
|
Former ID |
DIB012387
|
Drug Name |
LY2780301
|
Synonyms |
P70 S6 Kinase and AKT Dual Inhibitor
|
Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1]
|
Company |
Lilly
|
Target and Pathway |
Target(s) |
S6K kinase |
Target Info |
Modulator |
[2]
|
AKT3 protein kinase |
Target Info |
Modulator |
[2]
|
KEGG Pathway
|
MAPK signaling pathway
|
ErbB signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Chemokine signaling pathway
|
HIF-1 signaling pathway
|
FoxO signaling pathway
|
Sphingolipid signaling pathway
|
mTOR signaling pathway
|
PI3K-Akt signaling pathway
|
AMPK signaling pathway
|
Apoptosis
|
Adrenergic signaling in cardiomyocytes
|
VEGF signaling pathway
|
Osteoclast differentiation
|
Focal adhesion
|
Tight junction
|
Signaling pathways regulating pluripotency of stem cells
|
Platelet activation
|
Toll-like receptor signaling pathway
|
Jak-STAT signaling pathway
|
T cell receptor signaling pathway
|
B cell receptor signaling pathway
|
Fc epsilon RI signaling pathway
|
Fc gamma R-mediated phagocytosis
|
TNF signaling pathway
|
Neurotrophin signaling pathway
|
Cholinergic synapse
|
Dopaminergic synapse
|
Insulin signaling pathway
|
Progesterone-mediated oocyte maturation
|
Estrogen signaling pathway
|
Prolactin signaling pathway
|
Thyroid hormone signaling pathway
|
Adipocytokine signaling pathway
|
Glucagon signaling pathway
|
Regulation of lipolysis in adipocytes
|
Non-alcoholic fatty liver disease (NAFLD)
|
Carbohydrate digestion and absorption
|
Chagas disease (American trypanosomiasis)
|
Toxoplasmosis
|
Tuberculosis
|
Hepatitis C
|
Hepatitis B
|
Measles
|
Influenza A
|
HTLV-I infection
|
Epstein-Barr virus infection
|
Pathways in cancer
|
Proteoglycans in cancer
|
Colorectal cancer
|
Renal cell carcinoma
|
Pancreatic cancer
|
Endometrial cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Chronic myeloid leukemia
|
Acute myeloid leukemia
|
Small cell lung cancer
|
Non-small cell lung cancer
|
Central carbon metabolism in cancer
|
Choline metabolism in cancer
|
NetPath Pathway
|
TSH Signaling Pathway
|
IL2 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
Apoptosis signaling pathway
|
EGF receptor signaling pathway
|
Endothelin signaling pathway
|
FGF signaling pathway
|
Huntington disease
|
Hypoxia response via HIF activation
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
Interleukin signaling pathway
|
PI3 kinase pathway
|
T cell activation
|
p53 pathway
|
Ras Pathway
|
p53 pathway by glucose deprivation
|
p53 pathway feedback loops 2
|
Pathway Interaction Database
|
S1P3 pathway
|
Class I PI3K signaling events mediated by Akt
|
References |
REF 1 | ClinicalTrials.gov (NCT01115751) A Study in Patients With Advanced or Metastatic Cancer. U.S. National Institutes of Health. |
---|
REF 2 | A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9. |